Pyxis Oncology, Inc.(PYXS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PYXS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Pyxis Oncology, Inc. (PYXS), a Healthcare sector company. PYXS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Pyxis Oncology, Inc. reports net income of $-23.3M, free cash flow of $-26.0M. Top institutional holders of PYXS by reported 13-F value include PFIZER, Laurion Capital Management, GordonMD Global Investments, based on the most recent SEC filings. PYXS trades on the Nasdaq exchange and files with the SEC under CIK 1782223. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PYXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pyxis Oncology, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-23.3M
Free Cash Flow
Q1 2026
$-26.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-14.2% YoYNet Income
-3.0% YoYOperating Income
+5.6% YoYEPS (Diluted)
+3.0% YoYTotal Assets
-41.8% YoYOp. Cash Flow
-10.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $13.9M -14.2% | $16.1M | — | — | — | — |
| Net Income | $-79.6M -3.0% | $-77.3M -4.8% | $-73.8M +38.9% | $-120.7M -58.9% | $-76.0M -492.3% | $-12.8M |
| Operating Income | $-84.4M +5.6% | $-89.5M -8.8% | $-82.2M +33.4% | $-123.5M -77.1% | $-69.7M -440.7% | $-12.9M |
| EPS (Diluted) | $-1.28 +3.0% | $-1.32 +28.6% | $-1.85 +49.3% | $-3.65 +59.2% | $-8.95 | — |
| Total Assets | $91.5M -41.8% | $157.2M -9.5% | $173.7M -17.8% | $211.4M -24.5% | $280.0M +2658.6% | $10.2M |
| Operating Cash Flow | $-63.5M -10.1% | $-57.7M +18.4% | $-70.7M +20.8% | $-89.3M -152.9% | $-35.3M -250.3% | $-10.1M |
AI Insight: PYXS Ratio Trends
Pyxis Oncology is deeply unprofitable with accelerating losses; OpMargin deteriorated to -165.8% in Q4 2025 from -141.9% in Q1 2025.
• Operating margin worsened sharply to -165.8% in Q4 2025 from -141.9% in Q1 2025, signaling deteriorating cost control.
• Net profit margin declined to -164.0% in Q4 2025 from -131.0% in Q1 2025, mirroring operational weakness.
• ROA slipped to -79.1% in Q4 2025 from -62.3% in Q1 2025, indicating worsening asset utilization efficiency.
⚠ Persistent negative ROIC across all reported periods; Q1 2025 showed -88.9%, Q2 2025 -90.1%, indicating structural unprofitability.
⚠ ROE hit -135.6% in Q4 2025, the worst reading in dataset; trajectory suggests shareholder value destruction accelerating.
Get alerted when PYXS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Pyxis Oncology, Inc. including:
Top Institutional Holders of PYXS
PFIZER INC
$9.2M7,032,770 shLaurion Capital Management LP
$7.3M4,997,333 shGordonMD Global Investments LP
$6.0M4,121,870 shVANGUARD CAPITAL MANAGEMENT LLC
$3.0M2,033,510 shHealthInvest Partners AB
$1.6M197,036 shPalo Alto Investors LP
$1.5M1,010,510 sh683 Capital Management, LLC
$1.3M896,263 shRENAISSANCE TECHNOLOGIES LLC
$1.3M888,680 shBlackRock, Inc.
$1.2M788,839 shGEODE CAPITAL MANAGEMENT, LLC
$873.8K598,121 sh
| Fund | Value | Shares |
|---|---|---|
| PFIZER INC | $9.2M | 7,032,770 |
| Laurion Capital Management LP | $7.3M | 4,997,333 |
| GordonMD Global Investments LP | $6.0M | 4,121,870 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.0M | 2,033,510 |
| HealthInvest Partners AB | $1.6M | 197,036 |
| Palo Alto Investors LP | $1.5M | 1,010,510 |
| 683 Capital Management, LLC | $1.3M | 896,263 |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | 888,680 |
| BlackRock, Inc. | $1.2M | 788,839 |
| GEODE CAPITAL MANAGEMENT, LLC | $873.8K | 598,121 |
More Healthcare Companies
View all Healthcare →Put PYXS on your watchlist
Track score changes the day Pyxis Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PYXS a good stock to buy?
13F Pro's AI-powered analysis of Pyxis Oncology, Inc. (PYXS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PYXS are available on the PYXS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PYXS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PYXS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pyxis Oncology, Inc.'s investment landscape.